Table 2.
Cox proportional hazards regression models for the predictors of RFS in the LARC cohort (n = 242)
| Variables | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| RFS | HR (95% CI) | P value | Model A | Model B | ||
| HR (95% CI) | P value | HR (95% CI) | P value | |||
| Sex (male vs female) | 1.544 (0.967–2.466) | 0.069 | ||||
| Age >60 vs. ≤60 | 1.005 (0.641–1.576) | 0.983 | ||||
| Tumor grade (G1/2 vs. G3) | 1.257 (0.508–3.112) | 0.621 | ||||
| Tumor location (Medium/high vs. low) | 0.904 (0.574–1.422) | 0.662 | ||||
| In-TLS (no vs. yes) | 1.504 (0.877–2.577) | 0.138 | ||||
| Perineural invasion (no vs. yes) | 0.478 (0.292–0.785) | 0.004 | 0.751 (0.428–1.315) | 0.316 | 0.721 (0.407–1.274) | 0.260 |
| Vascular invasion (no vs. yes) | 0.354 (0.222–0.567) | <0.001 | 0.771 (0.446–1.331) | 0.350 | 0.791 (0.449–1.393) | 0.417 |
| TNM stage (III vs. II) | 3.498 (2.157–5.673) | <0.001 | 3.496 (2.108–5.799) | <0.001 | 3.017 (1.822–4.997) | <0.001 |
| CD8+ T cells (low vs. high) | 3.718 (2.212–6.250) | <0.001 | 1.935 (1.069–3.502) | 0.029 | 2.640 (1.517–4.593) | 0.001 |
| TLS density (low vs. high) | 3.513 (2.109–5.851) | <0.001 | 2.895 (1.612–5.200) | <0.001 | ||
| mTLS stage (mTLS- vs mTLS + ) | 2.567 (1.592–4.139) | <0.001 | 1.885 (1.125–3.159) | 0.016 | ||
| Adjuvant chemotherapy (FL/Capecitabine vs FOLFOX/XELOX) | 0.839 (0.571–1.398) | 0.621 | ||||